Prostate Cancer News and Research

Latest Prostate Cancer News and Research

FDA accepts Adamis IND for APC-100 to treat prostate cancer

FDA accepts Adamis IND for APC-100 to treat prostate cancer

9 Jun 2011
NYU Cancer Institute scientists present new research findings at ASCO 2011

NYU Cancer Institute scientists present new research findings at ASCO 2011

8 Jun 2011
Cabozantinib shows early promise in treatment of prostate cancer spread to the bone

Cabozantinib shows early promise in treatment of prostate cancer spread to the bone

8 Jun 2011
IsoRay completes Iotrex license agreement with Dr. Reddy's

IsoRay completes Iotrex license agreement with Dr. Reddy's

7 Jun 2011
FDA lifts BioSante's GVAX Prostate Cancer Vaccine clinical hold

FDA lifts BioSante's GVAX Prostate Cancer Vaccine clinical hold

7 Jun 2011
Exelixis reports encouraging interim data from cabozantinib phase 2 trial for metastatic CRPC

Exelixis reports encouraging interim data from cabozantinib phase 2 trial for metastatic CRPC

7 Jun 2011
Androgen deprivation therapy may increase risk of diabetes in men with prostate cancer

Androgen deprivation therapy may increase risk of diabetes in men with prostate cancer

6 Jun 2011
NCIC CTG's exemestane clinical trial data on breast cancer presented at ASCO 2011

NCIC CTG's exemestane clinical trial data on breast cancer presented at ASCO 2011

6 Jun 2011
Celgene announces results of REVLIMID, docetaxel/prednisone phase II combination study on mCRPC

Celgene announces results of REVLIMID, docetaxel/prednisone phase II combination study on mCRPC

6 Jun 2011
New targeted therapy may halt tumor growth in men with advanced prostate cancer

New targeted therapy may halt tumor growth in men with advanced prostate cancer

6 Jun 2011
Bayer's radium-223 chloride Phase III trial in CRPC, bone metastases meet primary endpoint

Bayer's radium-223 chloride Phase III trial in CRPC, bone metastases meet primary endpoint

6 Jun 2011
Ipsen decides to assess development of Irosustat in combination with hormonal therapies

Ipsen decides to assess development of Irosustat in combination with hormonal therapies

6 Jun 2011
Promising results from Exelixis' cabozantinib phase 2 trial against metastatic ovarian cancer

Promising results from Exelixis' cabozantinib phase 2 trial against metastatic ovarian cancer

6 Jun 2011
Five years after cancer treatment, many survivors still suffer symptoms

Five years after cancer treatment, many survivors still suffer symptoms

4 Jun 2011
SBRT is effective for patients with low-to-intermediate-risk prostate cancer: Researchers

SBRT is effective for patients with low-to-intermediate-risk prostate cancer: Researchers

4 Jun 2011
Delayed treatment could prove effective in certain medical conditions

Delayed treatment could prove effective in certain medical conditions

3 Jun 2011
ZYTIGA clinical study data on prostate cancer to be presented at ASCO 2011

ZYTIGA clinical study data on prostate cancer to be presented at ASCO 2011

3 Jun 2011
APC8015F investigational vaccine improves survival of prostate cancer patients

APC8015F investigational vaccine improves survival of prostate cancer patients

3 Jun 2011
Itraconazol may keep prostate cancer from worsening and delay need for chemotherapy in men

Itraconazol may keep prostate cancer from worsening and delay need for chemotherapy in men

3 Jun 2011
Stereotactic body radiation therapy effective for patients with low-risk prostate cancer

Stereotactic body radiation therapy effective for patients with low-risk prostate cancer

3 Jun 2011

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback